Brian Sowka
Internal Medicine · la Crosse, WINPI 1659834810
Payments from drug & device makers
Across 251 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$618
- Regeneron Healthcare Solutions, Inc.$448
- AbbVie$411
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$312
- Ardelyx, Inc.$282
- plus $920 from 11 others
What the payments were for
- Food & beverage$3,96190%
- Education$46110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 119 | $1,430 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $618 |
| Regeneron Healthcare Solutions, Inc. | 17 | $448 |
| AbbVie | 21 | $411 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $312 |
| Ardelyx, Inc. | 10 | $282 |
| Madrigal Pharmaceuticals | 5 | $264 |
| Phathom Pharmaceuticals, Inc. | 10 | $153 |
| Exact Sciences | 4 | $110 |
| Intercept Pharmaceuticals, Inc. | 5 | $97 |
| Celltrion USA Inc. | 3 | $78 |
| Sandoz | 2 | $63 |
| Boehringer Ingelheim | 3 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,422 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $32,926 |
| Mesalamine | 29 | $17,020 |
| MotegrityPrucalopride Succinate | 15 | $11,509 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 20 | $3,385 |
| Sucralfate | 14 | $953 |
| Omeprazole | 63 | $929 |
| Pantoprazole Sodium | 47 | $749 |
| Levothyroxine Sodium | 11 | $173 |
| Atorvastatin Calcium | 11 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $312 | $32,92612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $618 | $11,50915 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $21 | $3,38520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in la Crosse
- Sandra Sieckla Crosse$17K
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.